Journal article
Polo-like kinases in AML
Abstract
New therapies targeting critical elements of the cell cycle open novel and attractive avenues for the treatment of cancer patients. At present, the number of clinical trials that are registered with the European Organization for Research and Treatment of Cancer (EORTC) and with the US National Cancer Institute, which investigate the efficacy of Polo-like kinase 1 (Plk1) inhibitors against solid tumors and different types of leukemia is growing. …
Authors
Berg T; Bug G; Ottmann OG; Strebhardt K
Journal
Expert Opinion on Investigational Drugs, Vol. 21, No. 8, pp. 1069–1074
Publisher
Taylor & Francis
Publication Date
August 2012
DOI
10.1517/13543784.2012.691163
ISSN
1354-3784